Latest News

Named after King Nyabela of the Ndzundza-Ndebele people, the 220-bed district hospital will provide essential healthcare services to more than 240,000 residents of the Steve Tshwete Local Municipality.

Under the revised agreement, Exor can raise its shareholding in Philips to up to 22% of the company’s issued ordinary share capital and voting rights, compared with the previous 20% limit.

The procedures represent the first clinical use of the Aliya EX System since it received U.S. Food and Drug Administration (FDA) 510(k) clearance in May 2026.

Through the expanded partnership, Mayo Clinic will clinically integrate Exer AI’s hand and wrist module into its orthopaedic workflows to support musculoskeletal care.

The investment forms part of BMS’ broader US$ 40 billion commitment to strengthening its US operations, including its manufacturing and research and development (R&D) capabilities.

As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.

The AI-powered guidance will focus on building sustainable habits related to diet, physical activity, recovery and sleep, helping individuals make informed lifestyle decisions in real time.

The approval allows the company’s PGDx elio tissue complete CDx to be used in hospitals and clinical laboratories across the United States to help identify patients who may benefit from targeted treatment.

The approval from the Medicines and Healthcare products Regulatory Agency (MHRA) marks another milestone in the rapidly growing market for oral weight-loss medicines.

The agreement covers joint clinical studies that will combine BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors developed by Revolution Medicines: daraxonrasib, zoldonrasib, elironrasib and RMC-5127.